HUP0103601A2 - Hízósejtek degranulációját gátló hibrid protein és alkalmazása - Google Patents

Hízósejtek degranulációját gátló hibrid protein és alkalmazása

Info

Publication number
HUP0103601A2
HUP0103601A2 HU0103601A HUP0103601A HUP0103601A2 HU P0103601 A2 HUP0103601 A2 HU P0103601A2 HU 0103601 A HU0103601 A HU 0103601A HU P0103601 A HUP0103601 A HU P0103601A HU P0103601 A2 HUP0103601 A2 HU P0103601A2
Authority
HU
Hungary
Prior art keywords
hybrid protein
degranulation
mastocytes
inhibiting
known per
Prior art date
Application number
HU0103601A
Other languages
English (en)
Inventor
Hans Bigalke
Jürgen Frevert
Original Assignee
BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH filed Critical BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH
Publication of HUP0103601A2 publication Critical patent/HUP0103601A2/hu
Publication of HUP0103601A3 publication Critical patent/HUP0103601A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

A találmány szerinti hibrid protein i) egy önmagában ismertproteinből, amely önmagában ismert módon hízósejtekhez és/vagy bazofilsejtekhez kötődik és/vagy amelyeket hízósejtek és/vagy bazofil sejtekfelvesznek, és ii) egy önmagában ismert proteázból, amely a hízósejtekés/vagy bazofil sejtek kiválasztószervének egy vagy több proteinjéthasítja, áll vagy azokat tartalmazza. A találmány tárgyköréheztartozik továbbá a fenti hibrid protein alkalmazása hízósejtekdegranulációjának gátlására. Ó
HU0103601A 1998-05-13 1999-05-12 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof HUP0103601A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19821285 1998-05-13
PCT/EP1999/003272 WO1999058571A2 (de) 1998-05-13 1999-05-12 Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung

Publications (2)

Publication Number Publication Date
HUP0103601A2 true HUP0103601A2 (hu) 2002-01-28
HUP0103601A3 HUP0103601A3 (en) 2004-06-28

Family

ID=7867540

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103601A HUP0103601A3 (en) 1998-05-13 1999-05-12 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof

Country Status (22)

Country Link
EP (1) EP1084146B1 (hu)
JP (1) JP4549533B2 (hu)
KR (1) KR100580541B1 (hu)
CN (1) CN1241945C (hu)
AT (1) ATE227739T1 (hu)
AU (1) AU755513B2 (hu)
BR (1) BR9910359A (hu)
CA (1) CA2331274C (hu)
CU (1) CU22997A3 (hu)
CZ (1) CZ294376B6 (hu)
DE (1) DE59903410D1 (hu)
DK (1) DK1084146T3 (hu)
ES (1) ES2187200T3 (hu)
HK (1) HK1036994A1 (hu)
HU (1) HUP0103601A3 (hu)
IL (2) IL139478A0 (hu)
MX (1) MXPA00011148A (hu)
NO (1) NO328361B1 (hu)
PL (1) PL201879B1 (hu)
PT (1) PT1084146E (hu)
RU (1) RU2214420C2 (hu)
WO (1) WO1999058571A2 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
AU2001270219A1 (en) * 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
KR100845278B1 (ko) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 비만 세포의 활성을 유도하는 펩타이드 및 이를 포함하는면역조절제
US10240138B2 (en) 2008-06-12 2019-03-26 Ipsen Bioinnovation Limited Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
AU2009259033B2 (en) 2008-06-12 2013-11-07 Ipsen Bioinnovation Limited Suppression of neuroendocrine diseases
EP2318524B1 (en) * 2008-07-31 2016-02-24 Total Marketing Services Constructs and methods for the production and secretion of polypeptides
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN102241774B (zh) * 2010-05-27 2014-05-14 四川大学 重组IgE-Fc-抗EGFR单链抗体融合蛋白及其制备方法和用途
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10647750B2 (en) 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
JP2024509634A (ja) 2021-03-30 2024-03-04 イプセン バイオファーム リミテッド 疼痛及び炎症性障害の処置
CA3213914A1 (en) 2021-03-30 2022-10-06 Mikhail KALINICHEV Treatment of pain & inflammatory disorders
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
PL244930B1 (pl) 2021-12-08 2024-04-02 Gdanski Univ Medyczny Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
RU2214420C2 (ru) 2003-10-20
JP2002514659A (ja) 2002-05-21
PL344752A1 (en) 2001-11-19
NO20005637D0 (no) 2000-11-08
DK1084146T3 (da) 2003-02-03
CZ294376B6 (cs) 2004-12-15
NO328361B1 (no) 2010-02-01
CU22997A3 (es) 2004-10-12
KR20010042825A (ko) 2001-05-25
KR100580541B1 (ko) 2006-05-16
CZ20004161A3 (cs) 2001-04-11
AU4260599A (en) 1999-11-29
PT1084146E (pt) 2003-02-28
PL201879B1 (pl) 2009-05-29
HUP0103601A3 (en) 2004-06-28
EP1084146B1 (de) 2002-11-13
CN1300295A (zh) 2001-06-20
MXPA00011148A (es) 2003-04-22
WO1999058571A3 (de) 2000-02-03
IL139478A (en) 2008-06-05
ES2187200T3 (es) 2003-05-16
IL139478A0 (en) 2001-11-25
DE59903410D1 (de) 2002-12-19
BR9910359A (pt) 2001-01-09
AU755513B2 (en) 2002-12-12
CA2331274C (en) 2010-04-06
JP4549533B2 (ja) 2010-09-22
CN1241945C (zh) 2006-02-15
CA2331274A1 (en) 1999-11-18
ATE227739T1 (de) 2002-11-15
HK1036994A1 (en) 2002-01-25
NO20005637L (no) 2000-11-08
WO1999058571A2 (de) 1999-11-18
EP1084146A2 (de) 2001-03-21

Similar Documents

Publication Publication Date Title
HUP0103601A2 (hu) Hízósejtek degranulációját gátló hibrid protein és alkalmazása
AU2003275612A1 (en) Defructosylation method
DK1268847T3 (da) Ubiquitin-ligaseassay
NO20020348D0 (no) Peptid acceptor ligeringsmetoder
IS2714B (is) Uppsöfnun í frumu á phosphomate hliðstæðum á HIV próteasa hindrandi efnasamböndum
CY1111006T1 (el) Εκριμματαση ασθενειας alzheimer
TW200745552A (en) HU-ASP 1 protease substrate and uses thereof
FI962247A (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
DE69226636T2 (de) Stabilisierte enzyme
TR199902751T2 (xx) Proteaz inhibit�rleri.
BR9711540A (pt) Inibidores de protease proteìnico estabilizados e variantes dos mesmos
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
GB9919766D0 (en) Protein
WO2003072724A3 (en) Human analogs of murine deubiquitinating protease genes
DK1360306T3 (da) DNA-sekvens af enzymet phospholipase A1 fra ciliate Tetrahymena og anvendelse heraf
HUP0103974A2 (hu) A C. Albicans eszenciális génjei és antimikotikus anyagok szkrínelésére szolgáló eljárás az esszenciális gének alkalmazásával
DE69723456D1 (de) 1-(3-aminoindazol-5-yl)-3-phenylmethyl cyclische harnstoffe und ihre verwendung als hiv protease inhibitoren
ATE406446T1 (de) Vermehrungsproteine von pflanzen
DE69812597D1 (de) Peptide zur Inhibition von HPV E7 Proteinen
SE0100412D0 (sv) Novel human poly(A) polymerase
WO2003085103A3 (en) Purified polypeptides involved in nucleotide hydrolysis
AU2908400A (en) Protection of cells in connection with treatment with chemical agents
WO2004022702A3 (en) Methods and reagents for identifying inhibitors of viral protease activity.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees